文献速递儿童血液肿瘤与免疫

抗D免疫球蛋白与静脉免疫球蛋白治疗儿童免疫性血小板减少症的系统评价与Meta分析

Efficacy and Safety of Anti-D Immunoglobulins versus Intravenous Immunoglobulins for Immune Thrombocytopenia in Children: Systematic Review and Meta-analysis of Randomized Controlled Trials.
PubMed 文献 · J Pediatr · 2018-10-09

结果显示抗D在提升血小板计数方面显著劣于IVIG,但输注后一般症状更少,溶血更常见。总体证据质量低,IVIG可能更适合作为急性出血症状患儿的一线治疗。

要点

  • 抗D在24-72小时提升血小板至>20×10^9/L和>50×10^9/L的应答率均显著低于IVIG。
  • 抗D输注后一般症状发生率显著低于IVIG,但溶血更常见。
  • 出血应答因报告异质性结论不明确,总体研究质量低。

核心结论

  • 与抗D相比,IVIG在提升血小板计数方面应答更好,可能更适用于有急性出血症状的儿童ITP一线治疗。
  • IVIG在血小板计数上的优势其临床意义仍不明确。

研究设计与样本

  • 遵循PRISMA指南的系统评价与Meta分析,纳入评估抗D与IVIG在儿童ITP中疗效与安全性的随机对照试验。

主要发现

  • 抗D对比IVIG在24-72小时血小板>20×10^9/L的应答率比为0.85(95%CI 0.78-0.94)。
  • 抗D对比IVIG在24-72小时血小板>50×10^9/L的应答率比为0.75(95%CI 0.61-0.92)。
  • 抗D输注后一般症状少于IVIG(Peto OR 0.39,95%CI 0.25-0.62)。
  • 抗D后溶血比IVIG更常见。
  • 出血应答在4项研究中评估,但报告异质性导致结论不明确。

关键数值与推荐

  • 主要结局为各研究定义的血小板计数应答比例和出血应答。
  • 安全性结局包括输注反应和溶血。

临床怎么用

  • 对于有急性出血症状的儿童ITP,IVIG可能作为优先的一线治疗选择。
  • 选择抗D时需权衡其较低的输注一般症状发生率与较高的溶血风险。

局限性

  • 纳入研究的总体质量低。
  • 出血应答因报告异质性无法得出明确结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare the efficacy and safety of intravenous immunoglobulins (IVIG) and anti-D immunoglobulin (anti-D) in pediatric immune thrombocytopenia (ITP). STUDY DESIGN: We conducted a systematic review and meta-analysis following PRISMA guidelines, including all randomized controlled trials that have assessed the efficacy and safety of anti-D and IVIG in children with ITP. We searched Medline, Embase, and Cochrane databases. Primary outcomes were the proportion of children achieving platelet count responses as defined in each study and bleeding response. Other safety outcomes included infusion reactions and hemolysis. RESULTS: Eleven studies with 558 children were included. Anti-D was significantly inferior to IVIG at increasing platelet counts, both for thresholds of >20 × 109/L at 24-72 hours (response rate ratio for anti-D vs IVIG: 0.85, 95% CI 0.78-0.94) and >50 × 109/L at 24-72 hours (response rate ratio for anti-D vs IVIG: 0.75, 95% CI 0.61-0.92). Bleeding response was assessed in 4 studies, but some heterogeneity in reporting leads to unclear conclusion. General symptoms after anti-D infusion were less frequent than after IVIG (Peto OR 0.39, 95% CI 0.25-0.62). Hemolysis was more frequent after anti-D. The overall quality of the studies was low. CONCLUSIONS: Compared with anti-D, IVIG led to a better response in terms of platelet count and may be preferred as a first-line treatment of ITP in children with acute hemorrhagic symptoms. However, the clinical significance of IVIG superiority on platelet count remains unclear.

来源:J Pediatr,查看原文。版权归原作者所有。

引用

  1. Lioger B, Maillot F, Ternant D, et al. Efficacy and Safety of Anti-D Immunoglobulins versus Intravenous Immunoglobulins for Immune Thrombocytopenia in Children: Systematic Review and Meta-analysis of Randomized Controlled Trials. J Pediatr. 2018. PMID: 30314658. doi:10.1016/j.jpeds.2018.07.065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。